RU2012114854A - Способы лечения псориаза - Google Patents

Способы лечения псориаза Download PDF

Info

Publication number
RU2012114854A
RU2012114854A RU2012114854/15A RU2012114854A RU2012114854A RU 2012114854 A RU2012114854 A RU 2012114854A RU 2012114854/15 A RU2012114854/15 A RU 2012114854/15A RU 2012114854 A RU2012114854 A RU 2012114854A RU 2012114854 A RU2012114854 A RU 2012114854A
Authority
RU
Russia
Prior art keywords
individual
antibody
weeks
psoriasis
dose
Prior art date
Application number
RU2012114854/15A
Other languages
English (en)
Russian (ru)
Inventor
Хоакин Марио ВАЛЬДЕС
Эллиот К. ЧАРТАШ
Уилльям Т. БАРЧУК
Сьюзан К. ПОЛСОН
Кеннет В. ГОРДОН
Валид М. АВНИ
Яньжунь БАО
Уилльям Дж. ГЛАСС
Ихуа ГУ
Том К. ХАРРИС
Мартин КАУЛ
Парвез М. МУЛАНИ
Петер НЕРТЕРСХОЙЗЕР
Мартин М. ОКУН
Original Assignee
Эбботт Лэборетриз
Эбботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Лэборетриз, Эбботт Гмбх Унд Ко. Кг filed Critical Эбботт Лэборетриз
Publication of RU2012114854A publication Critical patent/RU2012114854A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2012114854/15A 2009-09-14 2010-09-14 Способы лечения псориаза RU2012114854A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24228809P 2009-09-14 2009-09-14
US61/242,288 2009-09-14
US24596709P 2009-09-25 2009-09-25
US61/245,967 2009-09-25
US29762310P 2010-01-22 2010-01-22
US61/297,623 2010-01-22
US36029910P 2010-06-30 2010-06-30
US61/360,299 2010-06-30
PCT/US2010/048771 WO2011032148A1 (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
RU2012114854A true RU2012114854A (ru) 2013-10-27

Family

ID=43732849

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012114854/15A RU2012114854A (ru) 2009-09-14 2010-09-14 Способы лечения псориаза

Country Status (15)

Country Link
US (2) US8557239B2 (enExample)
EP (1) EP2477654A4 (enExample)
JP (1) JP2013504598A (enExample)
KR (2) KR20120112384A (enExample)
CN (1) CN102630168A (enExample)
AU (1) AU2010291927A1 (enExample)
CA (1) CA2773556A1 (enExample)
IL (1) IL218633A0 (enExample)
IN (1) IN2012DN01965A (enExample)
MX (1) MX2012003138A (enExample)
NZ (1) NZ598722A (enExample)
RU (1) RU2012114854A (enExample)
SG (1) SG179135A1 (enExample)
TW (1) TW201127400A (enExample)
WO (1) WO2011032148A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090100461A (ko) * 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
NZ587765A (en) * 2008-03-18 2013-02-22 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
TW201233395A (en) * 2010-10-06 2012-08-16 Abbott Lab Methods for treating psoriasis
CN103857411A (zh) * 2011-07-13 2014-06-11 阿布维公司 使用抗il-13抗体治疗哮喘的方法和组合物
SG10201804954UA (en) * 2013-03-15 2018-07-30 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
BR112019005725A2 (pt) * 2016-09-23 2019-07-09 Abbvie Inc ajuste de dose
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
RU2697415C1 (ru) * 2018-11-12 2019-08-14 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения каплевидного псориаза
CN113015531A (zh) 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
JP2024510588A (ja) * 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
CA3212729A1 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN121175333A (zh) * 2023-04-26 2025-12-19 信达生物医药科技(杭州)有限公司 用重组白介素23p19抗体治疗银屑病的方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) * 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR0185192B1 (ko) * 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) * 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DK0614984T4 (da) * 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
AU7257696A (en) 1996-10-11 1998-05-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
PT936923E (pt) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
JP4481489B2 (ja) * 1998-01-23 2010-06-16 エフ．ホフマン−ラ ロシュ アーゲー ヒトｉｌ−１２に対する抗体
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
ATE305506T1 (de) * 1998-12-09 2005-10-15 Protein Design Labs Inc Verwendung von il-12 antikörpern zur behandlung von psoriasis
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
PL218748B1 (pl) * 1999-03-25 2015-01-30 Abbott Gmbh & Co Kg Wyizolowane przeciwciało ludzkie lub jego część wiążąca antygen, zawierająca je kompozycja farmaceutyczna, sposób hamowania aktywności ludzkiej IL-12 in vitro, zastosowanie przeciwciała lub jego części wiążącej antygen, sposób wykrywania ludzkiej IL-12, wyizolowana cząsteczka kwasu nukleinowego, zrekombinowany wektor ekspresyjny, komórka gospodarz oraz sposób syntetyzowania ludzkiego przeciwciała lub jego części wiążącej antygen
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
ES2562912T5 (es) * 2003-10-01 2020-02-18 Kyowa Hakko Kirin Co Ltd Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada
WO2005058294A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
EP1713502A1 (de) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
CA2591813A1 (en) * 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
HRP20130400T1 (en) * 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
KR20090100461A (ko) * 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
EP2142565A4 (en) * 2007-03-29 2010-03-31 Abbott Lab CRYSTALLINE HUMAN ANTI-IL-12 ANTIBODIES
NZ587765A (en) * 2008-03-18 2013-02-22 Abbott Lab Methods for treating psoriasis
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
TW201233395A (en) * 2010-10-06 2012-08-16 Abbott Lab Methods for treating psoriasis
TW201309330A (zh) * 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途

Also Published As

Publication number Publication date
JP2013504598A (ja) 2013-02-07
US20140079714A1 (en) 2014-03-20
SG179135A1 (en) 2012-05-30
US8557239B2 (en) 2013-10-15
IL218633A0 (en) 2012-05-31
AU2010291927A1 (en) 2012-04-12
IN2012DN01965A (enExample) 2015-08-21
NZ598722A (en) 2014-05-30
EP2477654A4 (en) 2013-01-23
KR20120112384A (ko) 2012-10-11
MX2012003138A (es) 2012-07-04
WO2011032148A1 (en) 2011-03-17
EP2477654A1 (en) 2012-07-25
TW201127400A (en) 2011-08-16
CN102630168A (zh) 2012-08-08
KR20140048229A (ko) 2014-04-23
US20110206680A1 (en) 2011-08-25
CA2773556A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
RU2012114854A (ru) Способы лечения псориаза
Uhlig et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome
Harper et al. GDF11 decreases pressure overload–induced hypertrophy, but can cause severe cachexia and premature death
Berntson et al. Cardiac autonomic balance versus cardiac regulatory capacity
Lam et al. Improving glycaemic and BP control in type 2 diabetes: the effectiveness of tai chi
Kataoka et al. The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction
US20230303678A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
RU2013120322A (ru) Способы лечения псориаза
CN102458376A (zh) 多巴胺激动剂加上第一时相胰岛素促分泌剂的组合物用于治疗代谢失调
Medved et al. Takotsubo cardiomyopathy after the first electroconvulsive therapy regardless of adjuvant beta-blocker use: a case report and literature review
Kurtzhals et al. The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide
Jun-Chi et al. Successful treatment of paediatric morphea with tofacitinib
US20080279819A1 (en) Combinations Therapy for Treatment of Demyelinating Conditions
US5378686A (en) Therapeutic treatment of fibromyalgia
Cozzolino et al. Acute pressor and hormonal effects of β-endorphin at high doses in healthy and hypertensive subjects: role of opioid receptor agonism
Choi et al. Coronary artery spasm induced by carotid sinus stimulation during neck surgery
Ahmed et al. Is testosterone replacement safe in men with cardiovascular disease?
Messer et al. Ketamine therapy for treatment-resistant depression in a patient with multiple sclerosis: A case report
Collins et al. Improvement in angina pectoris with alpha adrenoceptor blockade.
Zeng et al. Atorvastatin improves the cardiac function of rats after acute myocardial infarction through ERK1/2 pathway.
Aichhorn et al. Cardiomyopathy after long-term treatment with lithium–more than a coincidence?
Athanassopoulos et al. A case report:‘happy heart’syndrome in a patient treated with atomoxetine for attention deficit hyperactivity disorder
Nekrasov et al. The effect of rivaroxaban low doses on the stable angina of the II-III functional class clinical manifestations and the quality of life in patients with ischemic heart disease
Navinés et al. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders
Sands et al. The Rise of GLP-1 Agonists: A Review of Their Role in Weight Man-agement and Obesity Treatment

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant